DDInter132 DDInter1016
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Atomoxetine {u} (Compound) resembles {v} (Compound) Benzatropine
Atomoxetine {u} (Compound) resembles {v} (Compound) Fenoprofen
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Atomoxetine {u} (Compound) binds {v} (Gene) HTR2C
Atomoxetine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Atomoxetine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Atomoxetine {u} (Compound) downregulates {v} (Gene) FABP5
Atomoxetine {u} (Compound) causes {v} (Side Effect) Depressive symptom
Atomoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Atomoxetine (Compound) resembles Benzatropine (Compound)
Atomoxetine (Compound) resembles Fenoprofen (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Atomoxetine (Compound) binds HTR2C (Gene)
Atomoxetine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Atomoxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Atomoxetine (Compound) downregulates FABP5 (Gene)
Atomoxetine (Compound) causes Depressive symptom (Side Effect)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix